Zogenix to Present New Case Study Highlighting Successful Repositioning of Injectable Sumatriptan for Migraine With a Novel Needle-Free Delivery Technology
Mr. Turanin's presentation, which will take place at
"In today's marketplace, unique delivery technology can be a competitive advantage and a key driver of product adoption. In developing SUMAVEL DosePro, we successfully leveraged the unique properties of the DosePro needle-free delivery system to reposition the under-utilized standard subcutaneous treatment for migraine, sumatriptan injection, into a novel treatment option that simplifies the patient experience. As a result, we have seen increased utilization of injectable triptans," stated Mr. Turanin.
Turanin continued, "We view DosePro as an enabling delivery technology for both new and existing therapeutics that require or benefit from subcutaneous administration. It is particularly well suited for the delivery of highly viscous drug formulations such as biologics, which cannot be delivered via a traditional needle and syringe."
For more information on the DosePro needle-free delivery system, please visit www.DosePro.com.
About the 2nd Annual
Presenters and panelists will share with the audience best practices, new technologies, case studies, and regulatory developments in drug repositioning and indications discovery. It will feature a variety of speakers from academia, industry, non-profits and government. Their perspectives will provide insight into the field of drug repositioning and the challenges and successes in getting a repositioned drug to the marketplace. Building on last year's conference, the 2nd Annual
About SUMAVEL DosePro
SUMAVEL DosePro (sumatriptan injection) is indicated for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache episodes.
SUMAVEL DosePro should only be used where a clear diagnosis of migraine or cluster headache has been established. SUMAVEL DosePro is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine and should not be administered intravenously. For a given attack, if a patient does not respond to the first dose of SUMAVEL DosePro, the diagnosis of migraine or cluster headache should be reconsidered before administration of a second dose.
Important Safety Information
SUMAVEL DosePro is contraindicated in patients with uncontrolled hypertension, in patients with history, symptoms or signs of ischemic heart disease, coronary artery vasospasm, cerebrovascular or peripheral vascular disease including ischemic bowel disease and in patients with other significant underlying cardiovascular diseases or known hypersensitivity to sumatriptan. SUMAVEL DosePro should not be given to patients in whom unrecognized coronary artery disease is predicted by the presence of risk factors without a prior cardiovascular evaluation.
Serious cardiovascular events, including death, have been reported when taking sumatriptan, including patients with no findings of cardiovascular disease. Considering the extent of use of sumatriptan in patients with migraine, the incidence of these events is extremely low. Cerebrovascular events, some fatal, have been reported in patients treated with sumatriptan. In a number of cases, it appears possible that the cerebrovascular events were primary, sumatriptan having been administered in the incorrect belief the symptoms experienced were a consequence of migraine when they were not. It is important to advise patients not to administer SUMAVEL DosePro if a headache being experienced is atypical.
Do not use Sumavel DosePro and any ergotamine-containing or ergot-type medication within 24 hours of each other; do not use SUMAVEL DosePro and another 5-HT1 agonist (e.g. triptan) within 24 hours of each other (with the exception of a single dose of another sumatriptan product, provided the doses are separated by at least 1 hour). SUMAVEL DosePro is not generally recommended for use with MAO-A inhibitors. The development of a potentially life-threatening serotonin syndrome may occur with triptans, including treatment with SUMAVEL DosePro, particularly during combined use with selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). SUMAVEL DosePro should be used during pregnancy only if the potential benefit justifies the potential risk.
In controlled clinical trials with sumatriptan injection, the most common adverse reactions were injection site reactions, tingling, warm/hot sensation, burning sensation, feeling of heaviness, pressure sensation, feeling of tightness, numbness, feeling strange, tight feeling in head, flushing, tightness in chest, discomfort in nasal cavity/sinuses, jaw discomfort, dizziness/vertigo, drowsiness/sedation and headache.
For full prescribing information, please click here: http://www.zogenix.com/downloads/SV0468.0611_SDP_PI.pdf
For more information about SUMAVEL DosePro, please visit www.SUMAVELDosePro.com.
For additional information, please visit www.zogenix.com.
SUMAVEL®, DosePro®, ReldayTM and ZohydroTM are trademarks of
CONTACT: ZOGENIX INVESTORS:
Zack Kubow| The Ruth Group646.536.7020 | firstname.lastname@example.org ZOGENIX MEDIA: Victoria Aguiar| The Ruth Group646.536.7013 | email@example.com